GLG Partners’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

GLG Partners’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,000	Closed	-$26K	–	555
2016 Q4	$26K	Buy	+5,000	New	+$86.5K	﹤0.01%	362

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GLG Partners's ANTH Position: Q1 2017 in Review

GLG Partners sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 5,000 shares — an estimated $26K sold.

GLG Partners first reported a position in ANTH in Q4 2016 and held it in 1 quarter. The position peaked at $26K in Q4 2016. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

GLG Partners reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
GLG Partners sold 5,000 Anthera Pharmaceuticals, Inc. shares in Q1 2017, an estimated $26K.
GLG Partners first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
GLG Partners's Anthera Pharmaceuticals, Inc. position peaked at $26K in Q4 2016.
60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on GLG Partners's 13F filing for Q1 2017, filed 15 May 2017.